Kite, a Gilead Company, to present latest cell therapy research at the 2nd European CAR T Cell Meeting, Sitges, Spain
MEDIA ADVISORY
Kite, a Gilead Company, to present latest cell therapy research at the 2nd European CAR T Cell Meeting, Sitges, Spain
- Kite, a Gilead Company, is pleased to support the 2nd European CAR T Cell Meeting, taking place 30 January-01 February 2020 in Sitges, Spain.
- The meeting is jointly organised by the European Society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA) and will bring together clinicians and researchers working in gene and cell therapy from across Europe to discuss the latest research in chimeric antigen receptor T (CAR T) cell therapy.
- Kite will be presenting scientific, real-world and health economic data from its cell therapy research programmes to attending healthcare professionals.
- Bethany Dudek, Executive Director, Quality Head Europe, Kite, will participate in the ‘Manufacturing of CAR T cell in an Industrial setting’ session on Saturday 1 February (15:00-16:30 CET).
“We are pleased to be supporting the 2nd European CAR T Cell Meeting and look forward to presenting the latest data from our cell therapy research programme” said Dick Sundh, Vice President, Head of Europe, Kite. “The data we are presenting at this Meeting demonstrates Kite’s ongoing leadership in cell therapy and commitment to patient care.”
Presentations at the meeting will include:
|
Presentation Number and Date/Time (CET) |
Abstract Title |
|
Abstract #4814434 (Poster) Thursday, 30 January 2020 19:30-20:30 |
Real-world results of an anti-CD19 CAR T-cell (CAR) axicabtagene ciloleucel (axi-cel) for patients with relapsed/refractory large B-cell lymphoma included in a French Early Access Program - Catherine Thieblemont, MD, PhD, Hôpital Saint-Louis, Paris |
|
Abstract #4814519 (Oral) 17:45-18:45 |
Earlier steroid use with axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory large B cell lymphoma – Max S Topp, Head of Haematology at University Hospital of Wuerzburg |
|
Abstract #4813871 (Poster) Thursday, 30 January 2020 19:30-20:30
|
A comparison of 2-year outcomes in ZUMA-1 (axicabtagene ciloleucel) and SCHOLAR-1 in patients with refractory large B cell lymphoma - Sattva S Neelapu, The University of Texas MD Anderson Cancer Center, Houston |
|
Abstract #4813925 (Poster) Thursday, 30 January 2020 19:30-20:30 |
KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL): results of the Phase 2 ZUMA-2 study - Michael L Wang, The University of Texas MD Anderson Cancer Center, Houston |
|
Abstract: 4813993 (Poster) Thursday, 30 January 2020 19:30-20:30 |
Indirect Treatment Comparison of Axicabtagene Ciloluecel (Axi-Cel) Versus Tisagenlecleucel (Tisa-Cel) in Relapsed/Refractory Large B Cell Lymphoma (RR-LBCL) - Olalekan O Oluwole, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee |
|
Abstract: 4811334 (Oral) Friday, 31 January 2020 11:30-12:30 |
Are CAR Ts the same? Evidence from European HTA Reviews – Konstantinos Lykopoulos, Senior Director, Market Access and Reimbursement, Kite Pharma |
In August 2018, axicabtagene ciloleucel, a CAR T cell therapy, received European Marketing Authorisation for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy.[i]
The following experts will be available for comment on Kite activities at the meeting:
- Dick Sundh, Vice President, Head of Europe, Kite
- Bethany Dudek, Executive Director, Quality Head Europe, Kite
- Anne Kerber, Vice President, Head Clinical Development EU, Kite
For more information or to arrange a reactive interview please contact Cressida Robson, Media (Europe), Gilead (+44 7341 789 204 or Cressida.Robson@Gilead.com).
Editor Details
-
Company:
- Pharmiweb.com
-
Name:
- Kelly Tipper
- Email:
-
Telephone:
- +441344851506
